Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial (Q34644962)

3 August 2017

title

Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial (English)

1 reference

3 August 2017

0 references

0 references

0 references

1 reference

6

Marc C Levesque

1 reference

3 August 2017

1

Chester V Oddis

1 reference

3 August 2017

3

Rohit Aggarwal

1 reference

3 August 2017

Ann M Reed

2

1 reference

3 August 2017

Lisa G Rider

4

1 reference

3 August 2017

Dana P Ascherman

5

1 reference

3 August 2017

Richard J Barohn

7

1 reference

3 August 2017

Brian M Feldman

8

1 reference

3 August 2017

Michael O Harris-Love

9

1 reference

3 August 2017

Diane C Koontz

10

1 reference

3 August 2017

Noreen Fertig

11

1 reference

3 August 2017

Stephanie S Kelley

12

1 reference

3 August 2017

Sherrie L Pryber

13

1 reference

3 August 2017

Frederick W Miller

14

1 reference

3 August 2017

Howard E Rockette

15

1 reference

3 August 2017

RIM Study Group

16

1 reference

3 August 2017

language of work or name

1 reference

1 February 2013

1 reference

3 August 2017

published in

Arthritis & Rheumatology

1 reference

3 August 2017

volume

65

1 reference

3 August 2017

issue

2

1 reference

3 August 2017

page(s)

314-324

1 reference

Juvenile dermatomyositis: immunopathogenesis, role of myositis-specific autoantibodies, and review of rituximab use.

3 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3558563

Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3558563

Rituximab versus cyclophosphamide for ANCA-associated vasculitis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3558563

Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3558563

Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3558563

Rituximab in the treatment of dermatomyositis and other inflammatory myopathies. A report of 4 cases and review of the literature

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3558563

Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3558563

A double-blind, delayed-start trial of rasagiline in Parkinson's disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3558563

Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3558563

International consensus on preliminary definitions of improvement in adult and juvenile myositis.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3558563

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3558563

Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3558563

The evaluation of disease modifying therapies in Alzheimer's disease: a regulatory viewpoint

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3558563

Polymyositis: an overdiagnosed entity

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3558563

Defining Clinical Improvement in Adult and Juvenile Myositis.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3558563

Laboratory testing in the diagnosis and management of idiopathic inflammatory myopathies

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3558563

Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3558563

Incidence of polymyositis-dermatomyositis: a 20-year study of hospital diagnosed cases in Allegheny County, PA 1963-1982.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3558563

A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3558563

Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3558563

Rituximab treatment in patients with refractory inflammatory myopathies.

7 July 2018

1 reference

The delayed-start study design.

21 January 2018

1 reference

The randomized placebo-phase design for clinical trials.

21 January 2018

1 reference

Measurement of patient outcome in arthritis

21 January 2018

1 reference

Two simple, reliable and valid tests of proximal muscle function, and their application to the management of idiopathic inflammatory myositis

21 January 2018

1 reference

Reliability and validity of the myositis disease activity assessment tool

21 January 2018

1 reference

A novel autoantibody to a 155-kd protein is associated with dermatomyositis

21 January 2018

1 reference

International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies

21 January 2018

1 reference

Clinical and serologic characterization of an Argentine pediatric myositis cohort: identification of a novel autoantibody (anti-MJ) to a 142-kDa protein

21 January 2018

1 reference

12 December 2020

Safety and Efficacy of Rituximab in Severe Juvenile Dermatomyositis: Results from 9 Patients from the French Autoimmunity and Rituximab Registry

1 reference

12 December 2020

The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospect

1 reference

12 December 2020

Rituximab in the treatment of dermatomyositis: an open-label pilot study

1 reference

12 December 2020

Identifiers

DOI

10.1002/ART.37754

1 reference

3 August 2017

1 reference

3 August 2017

1 reference